Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the moving parts behind a global derivatives powerhouse can feel overwhelming. CME Group’s annual reports stretch past 200 pages, and its Form 4 insider notices drop without warning—often right before rate-sensitive futures rallies. If you have ever asked, “Where can I find CME Group’s quarterly earnings report 10-Q filing?” or “How do I decode clearinghouse risk in the 10-K?”, you are not alone.
Stock Titan solves this complexity. Our AI-powered summaries turn dense disclosures into plain-English briefs—so understanding CME Group SEC documents with AI becomes routine. Need CME Group insider trading Form 4 transactions? We stream CME Group Form 4 insider transactions real-time, flagging executive stock transactions the moment they reach EDGAR. Looking for revenue per contract or margin requirements? The platform highlights them automatically within the CME Group annual report 10-K simplified, while our dashboard links every footnote to the relevant accounting rule.
You will find every filing type—10-K, 10-Q, 8-K, DEF 14A, S-8—indexed and searchable. Click the 10-Q tab for a concise CME Group earnings report filing analysis; open any 8-K for CME Group 8-K material events explained in seconds. The proxy section answers, “What’s inside the CME Group proxy statement executive compensation?” by extracting pay ratio, incentive targets, and peer comparisons. Real-time alerts keep you ahead when material events hit or when directors buy shares. Whether you monitor fee trends, hedge fund positioning, or just want CME Group SEC filings explained simply, Stock Titan provides the clarity professionals need—all in one place.
CME Group insider Jonathan L. Marcus reported routine equity transactions in mid-September 2025. On September 15, 2025 he surrendered 259 Class A shares to the company to satisfy tax-withholding obligations related to restricted stock vesting, and on the same day he acquired 2,464 Class A shares at a price of $258.83 per share, leaving him with 8,913 shares beneficially owned. On September 16, 2025 he sold 376 Class A shares at $258.96 under a Rule 10b5-1 plan adopted February 18, 2025, and surrendered an additional 259 shares at $259.83 for tax withholding, resulting in 8,243 shares owned after those transactions. The filing is signed for Mr. Marcus on September 17, 2025.
Suzanne Sprague, COO & Global Head of Clearing of CME Group Inc. (CME), reported stock transactions related to the vesting of restricted shares. On 09/15/2025 she surrendered 639 Class A shares to the company to satisfy tax withholding upon vesting and simultaneously acquired 3,044 Class A shares, leaving her with 11,172 Class A shares after those transactions. On 09/16/2025 she surrendered an additional 325 Class A shares for tax withholding, leaving 10,847 Class A shares reported as beneficially owned.
The Form 4 indicates these transactions were to meet tax obligations tied to restricted stock vesting; no cash purchases or open-market sales are reported and no derivative transactions are disclosed.
Insider transactions at CME Group Inc. (CME)
Lynne Fitzpatrick, President and Chief Financial Officer, reported three Form 4 transactions related to restricted stock vesting on September 15-16, 2025. She surrendered 639 Class A shares on 09/15/2025 and 379 shares on 09/16/2025 to satisfy tax withholding obligations, at prices of $258.83 and $259.83 respectively. On 09/15/2025 she also acquired 4,348 Class A shares at $258.83, reflecting the net issuance from vesting. After these reported transactions, she beneficially owned 20,924 Class A shares directly.
Jack J. Tobin, MD Chief Accounting Officer of CME Group (CME), reported routine equity transactions tied to tax-withholding on vested restricted stock. The filing discloses three non-derivative transactions: on 09/15/2025 Mr. Tobin disposed of 143 shares at $258.83 to satisfy tax withholding and simultaneously acquired 1,546 shares at $258.83, leaving him with 25,142 shares after that activity. On 09/16/2025 he disposed of 57 shares at $259.83 for additional tax withholding, leaving 25,085 shares beneficially owned. The transactions are described as share surrenders to satisfy tax obligations upon vesting of restricted stock.
Michael G. Dennis, Global Head of Fixed Income at CME Group (CME), reported changes to his beneficial ownership in the company. On 09/15/2025 he acquired 2,608 Class A common shares at $258.83 each, bringing his direct holdings to 8,927.3766 shares. On 09/16/2025 he disposed of 289 shares at $259.83, leaving 8,638.3766 direct shares. The filing notes that the shares were surrendered to the company to satisfy tax withholding obligations upon the vesting of restricted stock on 09/16/2025. An additional 40.81 shares are held indirectly by his spouse.
Timothy Francis McCourt, Senior Managing Director, Global Head Equity & FX at CME Group Inc. (CME), reported changes in his beneficial ownership via a Form 4. On September 15, 2025 he surrendered 754 Class A shares to satisfy tax-withholding associated with restricted stock vesting and simultaneously acquired 2,752 Class A shares at $258.83 per share, bringing his direct holdings to 9,887 shares. On September 16, 2025 he surrendered an additional 379 shares at $259.83 per share for tax-withholding, leaving 9,508 shares beneficially owned after the transactions. The Form 4 was signed on behalf of Mr. McCourt on September 17, 2025.
Form 4 disclosure for Derek Sammann, Senior Managing Director, Global Head of Commodities Markets at CME Group (CME). The filing reports share surrender and vesting activity on September 15-16, 2025. Mr. Sammann surrendered 1,099 and 379 Class A shares to satisfy tax withholding obligations upon restricted stock vesting on those dates. The filing lists direct beneficial ownership amounts of 8,318; 11,362; and 10,983 Class A shares after respective transactions, and shows indirect holdings of 14,614 shares held by a trust and 8,336 shares held by his spouse. The form was signed on 09/17/2025.
Terrence A. Duffy, Chairman and CEO and a director of CME Group Inc. (CME), reported a purchase of 23,180 shares of Class A Common Stock on 09/15/2025 at a reported price of $258.83 per share. After the transaction he beneficially owns 90,804 shares. The Form 4 was signed on behalf of the reporting person by Margaret Austin Wright on 09/17/2025. No derivative transactions were reported.
Hilda Harris Piell, Sr. MD & Chief HR Officer at CME Group (CME), reported insider transactions on Form 4 showing share surrenders to cover tax withholding upon restricted stock vesting. On 09/15/2025 she disposed of 953 Class A shares at $258.83 each, reducing her holdings to 28,108 shares, and on the same date acquired 2,608 shares at $258.83, raising holdings to 30,716 shares. On 09/16/2025 she disposed of 325 shares at $259.83, leaving 30,391 shares beneficially owned after the reported transactions. The filing states the disposals were share surrenders to satisfy tax-withholding obligations tied to restricted stock vesting; the form was signed on 09/17/2025.
CME Group Inc. filed a Form 144 notifying of a proposed sale of 376 shares of common stock through Morgan Stanley Smith Barney LLC, for an aggregate market value of $97,368.96. The shares were acquired as restricted stock from the issuer on 09/15/2025 and the proposed sale date is 09/16/2025 on NASDAQ. The filing shows 360,377,042 shares outstanding, and the filer states they are unaware of any undisclosed material adverse information. No sales by the filer in the past three months are reported.
FAQ
What is the current stock price of CME Group (CME)?
What is the market cap of CME Group (CME)?
